EA016071B1 - Соединения и способы лечения или предотвращения флавивирусных инфекций - Google Patents

Соединения и способы лечения или предотвращения флавивирусных инфекций Download PDF

Info

Publication number
EA016071B1
EA016071B1 EA200702493A EA200702493A EA016071B1 EA 016071 B1 EA016071 B1 EA 016071B1 EA 200702493 A EA200702493 A EA 200702493A EA 200702493 A EA200702493 A EA 200702493A EA 016071 B1 EA016071 B1 EA 016071B1
Authority
EA
Eurasian Patent Office
Prior art keywords
trans
amino
thiophene
optionally substituted
methylcyclohexanecarbonyl
Prior art date
Application number
EA200702493A
Other languages
English (en)
Russian (ru)
Other versions
EA200702493A1 (ru
Inventor
Реал Дени
Карл Пуассон
Санджой Кумар Дас
Ирина Моторина
Рабиндра Редж
Константин Г. Яннопулос
Лаваль Чань Чунь Кун
Original Assignee
Вирокем Фарма Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Вирокем Фарма Инк. filed Critical Вирокем Фарма Инк.
Publication of EA200702493A1 publication Critical patent/EA200702493A1/ru
Publication of EA016071B1 publication Critical patent/EA016071B1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D333/40Thiophene-2-carboxylic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
EA200702493A 2005-05-13 2006-05-15 Соединения и способы лечения или предотвращения флавивирусных инфекций EA016071B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68048205P 2005-05-13 2005-05-13
PCT/CA2006/000786 WO2006119646A1 (en) 2005-05-13 2006-05-15 Compounds and methods for the treatment or prevention of flavivirus infections

Publications (2)

Publication Number Publication Date
EA200702493A1 EA200702493A1 (ru) 2008-04-28
EA016071B1 true EA016071B1 (ru) 2012-01-30

Family

ID=37396165

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200702493A EA016071B1 (ru) 2005-05-13 2006-05-15 Соединения и способы лечения или предотвращения флавивирусных инфекций

Country Status (16)

Country Link
US (3) US7569600B2 (cg-RX-API-DMAC7.html)
EP (3) EP2546246A3 (cg-RX-API-DMAC7.html)
JP (1) JP5030947B2 (cg-RX-API-DMAC7.html)
KR (1) KR20080016597A (cg-RX-API-DMAC7.html)
CN (2) CN101218224B (cg-RX-API-DMAC7.html)
AP (1) AP2007004245A0 (cg-RX-API-DMAC7.html)
AU (1) AU2006246227B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0610283A2 (cg-RX-API-DMAC7.html)
CA (1) CA2607359C (cg-RX-API-DMAC7.html)
EA (1) EA016071B1 (cg-RX-API-DMAC7.html)
ES (1) ES2415742T3 (cg-RX-API-DMAC7.html)
MX (1) MX2007014117A (cg-RX-API-DMAC7.html)
NZ (1) NZ563909A (cg-RX-API-DMAC7.html)
SG (1) SG161315A1 (cg-RX-API-DMAC7.html)
WO (1) WO2006119646A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200709727B (cg-RX-API-DMAC7.html)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4544857B2 (ja) * 2001-06-11 2010-09-15 ヴァイロケム ファーマ インコーポレイテッド Flavivirus感染の治療または予防のための化合物および方法
US8329924B2 (en) * 2001-06-11 2012-12-11 Vertex Pharmaceuticals (Canada) Incorporated Compounds and methods for the treatment or prevention of Flavivirus infections
EP2546246A3 (en) * 2005-05-13 2013-04-24 Virochem Pharma Inc. Compounds and methods for the treatment or prevention of flavivirus infections
AU2007321677B2 (en) 2006-11-15 2013-04-11 Vertex Pharmaceuticals (Canada) Incorporated Thiophene analogues for the treatment or prevention of flavivirus infections
JP2010521457A (ja) * 2007-03-12 2010-06-24 メルク・シャープ・エンド・ドーム・コーポレイション 単環式アニリドスピロラクタムcgrp受容体アンタゴニスト
DK2308514T3 (da) 2007-03-23 2013-09-02 To Bbb Holding B V Konjugater til målrettet lægemiddeltransport gennem blod-hjerne barrieren
JP2010526143A (ja) 2007-05-04 2010-07-29 バーテックス ファーマシューティカルズ インコーポレイテッド Hcv感染の処置のための併用療法
PH12012502343A1 (en) 2007-05-23 2013-06-17 Siga Tech Inc Antiviral drugs for treatment or prevention of dengue infection
GB0712393D0 (en) * 2007-06-26 2007-08-01 Smithkline Beecham Corp Compounds
CN101903351B (zh) 2007-12-19 2014-09-10 贝林格尔.英格海姆国际有限公司 病毒聚合酶抑制剂
US20110212986A1 (en) * 2008-08-21 2011-09-01 Health Research, Inc. Anti-flavivirus therapeutic
RU2011127080A (ru) 2009-01-07 2013-02-20 Сайнексис, Инк. Производное циклоспорина для применения в лечении заражения вирусом гепатита с и вич
JP5327744B2 (ja) * 2009-03-13 2013-10-30 国立大学法人 鹿児島大学 ジフェニルメタン誘導体を有効成分とする抗ウイルス剤
AU2010276441B2 (en) * 2009-07-21 2015-07-02 Gilead Sciences, Inc. Inhibitors of Flaviviridae viruses
KR20120081123A (ko) 2009-09-09 2012-07-18 길리애드 사이언시즈, 인코포레이티드 플라비비리대 바이러스의 억제제
EP2477982A4 (en) * 2009-09-16 2013-04-03 Calcimedica Inc COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM
JP2013512247A (ja) 2009-11-25 2013-04-11 バーテックス ファーマシューティカルズ インコーポレイテッド フラビウイルス感染症の治療または予防のための5−アルキニル−チオフェン−2−カルボン酸誘導体およびそれらの使用
SI2523950T1 (sl) 2010-01-15 2017-06-30 Gilead Sciences, Inc. Inhibitorji flaviviridae virusov
WO2011088303A1 (en) * 2010-01-15 2011-07-21 Gilead Sciences , Inc. Inhibitors of flaviviridae viruses
MX2012014918A (es) 2010-06-28 2013-04-08 Vertex Pharma Compuestos y metodos para tratamiento o prevencion de infecciones por flavivirus.
WO2012006060A1 (en) * 2010-06-28 2012-01-12 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
WO2012024363A2 (en) 2010-08-17 2012-02-23 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flaviviridae viral infections
WO2012083105A1 (en) 2010-12-17 2012-06-21 Cocrystal Discovery, Inc. Inhibitors of hepatitis c virus polymerase
US20130203706A1 (en) * 2011-06-28 2013-08-08 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
PT2734515E (pt) * 2011-07-13 2016-03-11 Gilead Sciences Inc Derivados de ácido tiofen-2-carboxílico úteis como inibidores de vírus flaviviridae
CN103059042B (zh) * 2011-10-18 2015-10-07 银杏树药业(苏州)有限公司 噻吩类衍生物及其在药学中的用途
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
CN104023726A (zh) 2011-10-21 2014-09-03 艾伯维公司 用于治疗hcv的一种或多种daa的联合治疗(例如,与abt-072或abt-333)
GB2506086A (en) 2011-10-21 2014-03-19 Abbvie Inc Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
CN103087052A (zh) * 2011-10-31 2013-05-08 上海壹志医药科技有限公司 噻吩衍生物及其药物用途
WO2014055142A1 (en) 2012-06-20 2014-04-10 Cocrystal Discovery, Inc. Inhibitors of hepatitis c virus polymerase
US8841340B2 (en) 2012-08-17 2014-09-23 Gilead Sciences, Inc. Solid forms of an antiviral compound
US8927741B2 (en) 2012-08-17 2015-01-06 Gilead Sciences, Inc. Synthesis of an antiviral compound
US8759544B2 (en) 2012-08-17 2014-06-24 Gilead Sciences, Inc. Synthesis of an antiviral compound
TWI731854B (zh) 2015-03-23 2021-07-01 美商共結晶製藥公司 C型肝炎病毒聚合酶之抑制劑
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
CN106467477A (zh) * 2016-08-26 2017-03-01 天津雅奥科技发展有限公司 一种合成化合物(1‑环丙基‑1‑氰基‑4‑环己酮)的新方法
MX2020011912A (es) 2018-05-09 2021-01-29 Cocrystal Pharma Inc Terapia de combinacion para el tratamiento del virus de la hepatitis c (vhc).
CR20200618A (es) 2018-06-19 2021-01-21 Novartis Ag Derivados de tetrahidrotienopiridina n-sustituidos y sus usos
CN110592172B (zh) * 2019-10-29 2021-05-28 华中农业大学 利用CRISPR/Cas9敲除文库技术筛选JEV抗性基因的方法与靶点
CN111518015A (zh) * 2020-05-20 2020-08-11 上海合全药物研发有限公司 一种叔丁基-8-氧亚基-2-氮杂螺[4.5]癸烷-2-甲酸基酯的制备方法
CN113861176B (zh) * 2021-09-28 2023-11-03 北京凯因格领生物技术有限公司 一种黄病毒抑制剂
EP4282862A1 (en) * 2022-05-25 2023-11-29 Irbm S.P.A. Flavivirus inhibitors
WO2024254161A2 (en) * 2023-06-05 2024-12-12 Celloram Inc. Inhibitors of fatty acid binding proteins (fabps), methods of use and methods of making

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2496680A1 (en) * 1997-04-28 1998-11-05 Encysive Pharmaceuticals Inc. Sulfonamide compounds and salts for treatment of endothelin-mediated disorders

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3076817A (en) * 1963-02-05 New j-amino-thiophene-z
DE1055007B (de) 1957-08-29 1959-04-16 Dr Hans Fiesselmann Verfahren zur Herstellung von 3-Aminothiophen-2-carbonsaeureestern und den entsprechenden freien Carbonsaeuren
US3470151A (en) 1966-05-17 1969-09-30 Beecham Group Ltd Furyl- and thienyl-penicillins and salts thereof
AU518216B2 (en) * 1977-09-06 1981-09-17 Hafslund Nycomed Pharma Aktiengesellschaft Thienothiazine derivatives
GB8627698D0 (en) 1986-11-20 1986-12-17 Boots Co Plc Therapeutic agents
US4962101A (en) 1989-08-21 1990-10-09 Merck & Co., Inc. 2-(Heterocyclylalkyl)phenyl carbapenem antibacterial agents
JPH0748360A (ja) 1993-05-31 1995-02-21 Yoshitomi Pharmaceut Ind Ltd ビフェニルテトラゾール誘導体
JP4080541B2 (ja) 1996-10-18 2008-04-23 バーテックス ファーマシューティカルズ インコーポレイテッド セリンプロテアーゼ、特にc型肝炎ウイルスns3プロテアーゼの阻害因子
JP4000608B2 (ja) * 1996-11-07 2007-10-31 トヨタ自動車株式会社 水素製造充填装置および電気自動車
TW523506B (en) * 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
WO1998046588A2 (en) * 1997-04-11 1998-10-22 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
US5783705A (en) * 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
DE69826695T2 (de) 1997-05-23 2006-02-02 Bayer Pharmaceuticals Corp., West Haven Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen
DE69839639D1 (en) 1997-05-23 2008-08-07 Bayer Pharmaceuticals Corp Raf kinase hemmer
US6187799B1 (en) * 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
HUP0004853A3 (en) 1997-08-11 2001-12-28 Boehringer Ingelheim Ca Ltd Hepatitis c inhibitor peptides, process for preparation thereof, pharmaceutical compositions comprising thereof, their use and their intermediates
DE69827956T2 (de) 1997-08-11 2005-04-14 Boehringer Ingelheim (Canada) Ltd., Laval Peptidanaloga mit inhibitorischer wirkung auf hepatitis c
ATE228119T1 (de) * 1998-04-15 2002-12-15 Pfizer Prod Inc Heterocyclische carboxamide
EP0960882A1 (en) * 1998-05-19 1999-12-01 Hoechst Marion Roussel Deutschland GmbH Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists
US6858223B2 (en) * 1998-06-23 2005-02-22 Altana Pharma Ag Compositions comprising phenylaminothiophenacetic acid derivatives for the treatment of acute or adult respiratory distress syndrome (ARDS) and infant respiratory distress syndrome (IRDS)
ATE253061T1 (de) * 1998-06-29 2003-11-15 Iaf Biochem Int Zur behandlung von krebs nützliche thiophen- und furan-2,5-dicarboxamide
ES2244204T3 (es) 1998-07-27 2005-12-01 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Derivados de dicetoacidos como inhibidores de polimerasas.
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
AR022061A1 (es) 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
HRP20010206A2 (en) 1998-08-20 2004-02-29 Agouron Pharma NON-PEPTIDE GnRH AGENTS, METHODS AND INTERMEDIATES FOR THEIR PREPARATION
DE19903398A1 (de) 1999-01-29 2000-08-10 Hassan Jomaa Verwendung von Thiadiazolderivaten zur prophylaktischen und therapeutischen Behandlung von Infektionen
WO2000055139A2 (en) * 1999-03-12 2000-09-21 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic urea and related compounds useful as anti-inflammatory agents
UA74546C2 (en) 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
JP2001010957A (ja) 1999-04-28 2001-01-16 Sankyo Co Ltd 肝障害の予防または抑制剤
DE19920247A1 (de) 1999-05-03 2000-11-16 Hassan Jomaa Arzneimittel mit einem Gehalt an Verbindungen mit einem Stickstoff-Sauerstoff-Heterocyclus als Wirkstoff und ihre Verwendung
HN2000000051A (es) * 1999-05-19 2001-02-02 Pfizer Prod Inc Derivados heterociclicos utiles como agentes anticancerosos
CA2385972A1 (en) 1999-10-01 2001-04-12 Haruhisa Ogita Novel diarylamide derivatives and use thereof as medicines
DE60008416D1 (de) * 1999-11-29 2004-03-25 Novartis Ag Pestizide n-heteroaryl alpha-alkoximinocarbonsäureamide
WO2001047883A1 (fr) 1999-12-27 2001-07-05 Japan Tobacco Inc. Composes a cycles accoles et leur utilisation comme medicaments
DE10002424A1 (de) * 2000-01-20 2001-07-26 Siemens Ag Di(het)arylaminothiophen-Derivate
AU2001261377A1 (en) 2000-05-10 2001-11-20 Smith Kline Beecham Corporation Novel anti-infectives
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
US6414013B1 (en) * 2000-06-19 2002-07-02 Pharmacia & Upjohn S.P.A. Thiophene compounds, process for preparing the same, and pharmaceutical compositions containing the same background of the invention
GB0017676D0 (en) 2000-07-19 2000-09-06 Angeletti P Ist Richerche Bio Inhibitors of viral polymerase
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
WO2002028353A2 (en) 2000-10-05 2002-04-11 Smithkline Beecham Corporation Phosphate transport inhibitors
EG23122A (en) 2000-11-08 2004-04-28 Syngenta Participations Ag Pyrrolcarboxamides and pyrrolcarbothioamides
ES2263687T3 (es) 2000-11-20 2006-12-16 Bristol-Myers Squibb Company Inhibidores tripeptidicos de la hepatitis c.
US6892279B2 (en) * 2000-11-30 2005-05-10 Mosaid Technologies Incorporated Method and apparatus for accelerating retrieval of data from a memory system with cache by reducing latency
DE10061876A1 (de) * 2000-12-12 2002-06-20 Aventis Pharma Gmbh Arylierte Furan- und Thiophencarbonsäureamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
ATE526339T1 (de) 2001-01-22 2011-10-15 Merck Sharp & Dohme Nukleosidderivate als inhibitoren der rna- abhängigen viralen rna-polymerase
AU2002252183A1 (en) 2001-03-06 2002-09-19 Biocryst Pharmaceuticals, Inc. Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases
US6734207B2 (en) * 2001-04-20 2004-05-11 Parker Hughes Institute Cytotoxic compounds
EP1256628A3 (en) 2001-05-10 2003-03-19 Agouron Pharmaceuticals, Inc. Hepatitis c virus (hcv) ns5b rna polymerase and mutants thereof
US6713638B2 (en) * 2001-05-18 2004-03-30 Joel M. Linden 2-amino-3-aroyl-4,5 alkylthiophenes: agonist allosteric enhancers at human A1 adenosine receptors
AR036081A1 (es) 2001-06-07 2004-08-11 Smithkline Beecham Corp Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos
EP1395571A1 (en) 2001-06-11 2004-03-10 Shire Biochem Inc. Compounds and methods for the treatment or prevention of flavivirus infections
JP4544857B2 (ja) 2001-06-11 2010-09-15 ヴァイロケム ファーマ インコーポレイテッド Flavivirus感染の治療または予防のための化合物および方法
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
SE0102617D0 (sv) * 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
WO2003026587A2 (en) 2001-09-26 2003-04-03 Bristol-Myers Squibb Company Compounds useful for treating hepatitus c virus
ATE414697T1 (de) * 2001-10-04 2008-12-15 Smithkline Beecham Corp Nf-kb-inhibitoren
MXPA04003825A (es) 2001-10-24 2004-07-08 Vertex Pharma Inhibidores de serina proteasa, en particular la ns3-ns4a proteasa del virus de hepatitis c, que incorpora un sistema de anillo fusionado.
TWI281916B (en) * 2001-10-25 2007-06-01 Lilly Co Eli Antitumor compounds and methods
AU2002352443A1 (en) * 2001-12-21 2003-07-15 Consejo Superior De Investigaciones Cientificas Compounds and their therapeutic use related to the phosphorylating activity of the enzyme gsk-3
US6835745B2 (en) * 2002-01-15 2004-12-28 Wyeth Phenyl substituted thiophenes as estrogenic agents
DE10203122A1 (de) 2002-01-25 2003-07-31 Gruenenthal Gmbh Verfahren zur Herstellung von substituierten Acrylsäureestern bzw. deren Einsatz zur Herstellung von substituierten gamma-Aminosäuren
MXPA04009938A (es) 2002-04-11 2004-12-13 Vertex Pharma Inhibidores de serina proteasas, en particular la proteasa ns3-ns4a del hcv.
JP2005530759A (ja) 2002-05-06 2005-10-13 ジェネラブズ テクノロジーズ インコーポレーティッド C型肝炎ウイルス感染症を治療するためのヌクレオシド誘導体
JP2005538953A (ja) * 2002-05-28 2005-12-22 3−ディメンショナル ファーマシューティカルズ, インコーポレイテッド 新規チオフェンアミジン、それらの組成物、および補体媒介疾患および病気を治療する方法
US7179836B2 (en) * 2002-09-20 2007-02-20 Smithkline Beecham Corporation Chemical compounds
WO2004052879A1 (en) 2002-12-10 2004-06-24 Virochem Pharma Inc. Thiophenederivatives for the treatment of flavivirus infections
PT1569929E (pt) 2002-12-10 2010-06-18 Virochem Pharma Inc Compostos e métodos para o tratamento ou prevenção de infecções por flavivírus
JP4926403B2 (ja) 2002-12-10 2012-05-09 ヴァイロケム ファーマ インコーポレイテッド フラビウイルス感染の処置もしくは予防のための化合物および方法
US7098241B2 (en) * 2002-12-16 2006-08-29 Hoffmann-La Roche Inc. Thiophene hydroxamic acid derivatives
US20050090450A1 (en) 2003-04-11 2005-04-28 Farmer Luc J. Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
EP1613620A1 (en) 2003-04-11 2006-01-11 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
US20050113566A1 (en) 2003-04-25 2005-05-26 Player Mark R. Inhibitors of C-FMS kinase
CA2523808A1 (en) 2003-05-16 2004-12-23 Ambit Biosciences Corporation Pyrrole compounds and uses thereof
US7345046B2 (en) 2003-05-30 2008-03-18 Chiron Corporation Heteroaryl-fused pyrimidinyl compounds as anticancer agents
US7109172B2 (en) 2003-07-18 2006-09-19 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
TWI359147B (en) 2003-09-05 2012-03-01 Vertex Pharma Inhibitors of serine proteases, particularly hcv n
US20050119189A1 (en) 2003-09-18 2005-06-02 Cottrell Kevin M. Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
GB0324653D0 (en) 2003-10-22 2003-11-26 Syngenta Participations Ag Fungicides
DE10359791A1 (de) * 2003-12-19 2005-07-21 Bayer Healthcare Ag Substituierte Thiophene
EP1711515A2 (en) 2004-02-04 2006-10-18 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
WO2006093518A2 (en) 2004-06-25 2006-09-08 Apath, Llc Thienyl compounds for treating virus-related conditions
CA2573185A1 (en) 2004-07-14 2006-02-23 Ptc Therapeutics, Inc. Methods for treating hepatitis c
FR2873692B1 (fr) 2004-07-29 2006-12-01 Univ Claude Bernard Lyon COMPOSITIONS CONTENANT, EN ASSOCIATION AVEC UN AGENT ANTIMICROBIEN, UN COMPOSE THIOPHENIQUE OU BENZOTHIOPHENIQUE DE FORMULE(I)PRESENTANT UNE ACTIVITE INHIBITRICE DE POMPE NorA
MX2007003812A (es) 2004-10-01 2007-05-24 Vertex Pharma Inhibicion de proteasa ns3-ns4a del virus de la hepatitis c (vhc).
DE102005028077A1 (de) 2004-12-22 2006-07-13 Aicuris Gmbh & Co. Kg Alkinyl-substituierte Thiophene
DE102004061746A1 (de) 2004-12-22 2006-07-06 Bayer Healthcare Ag Alkinyl-substituierte Thiophene
EP2546246A3 (en) * 2005-05-13 2013-04-24 Virochem Pharma Inc. Compounds and methods for the treatment or prevention of flavivirus infections
JP2006334109A (ja) 2005-06-01 2006-12-14 Matsushita Electric Works Ltd ヘアセット装置
AU2007321677B2 (en) 2006-11-15 2013-04-11 Vertex Pharmaceuticals (Canada) Incorporated Thiophene analogues for the treatment or prevention of flavivirus infections

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2496680A1 (en) * 1997-04-28 1998-11-05 Encysive Pharmaceuticals Inc. Sulfonamide compounds and salts for treatment of endothelin-mediated disorders
WO1998049162A1 (en) * 1997-04-28 1998-11-05 Texas Biotechnology Corporation Sulfonamides for treatment of endothelin-mediated disorders

Also Published As

Publication number Publication date
CA2607359C (en) 2011-08-09
AU2006246227A1 (en) 2006-11-16
JP2008540463A (ja) 2008-11-20
US20060276533A1 (en) 2006-12-07
US7569600B2 (en) 2009-08-04
EP2543664A1 (en) 2013-01-09
KR20080016597A (ko) 2008-02-21
JP5030947B2 (ja) 2012-09-19
BRPI0610283A2 (pt) 2010-10-19
CN101218224A (zh) 2008-07-09
ZA200709727B (en) 2008-11-26
US20120164103A1 (en) 2012-06-28
EP1879879B1 (en) 2013-03-27
WO2006119646A1 (en) 2006-11-16
US20100093775A1 (en) 2010-04-15
CN102718744A (zh) 2012-10-10
CN101218224B (zh) 2013-05-08
MX2007014117A (es) 2008-02-05
NZ563909A (en) 2011-10-28
CA2607359A1 (en) 2006-11-16
US8158675B2 (en) 2012-04-17
EP1879879A1 (en) 2008-01-23
ES2415742T3 (es) 2013-07-26
AP2007004245A0 (en) 2007-12-31
EA200702493A1 (ru) 2008-04-28
EP2546246A3 (en) 2013-04-24
AU2006246227B2 (en) 2011-04-28
EP1879879A4 (en) 2010-03-10
HK1112910A1 (en) 2008-09-19
EP2546246A2 (en) 2013-01-16
SG161315A1 (en) 2010-05-27
US8674118B2 (en) 2014-03-18

Similar Documents

Publication Publication Date Title
EA016071B1 (ru) Соединения и способы лечения или предотвращения флавивирусных инфекций
US10765676B2 (en) Trk-inhibiting compound
EP2297133B1 (en) 1, 2 disubstituted heterocyclic compounds
JP5290186B2 (ja) フラビウイルス感染症の治療または予防用のチオフェン類似体
CA2508990C (en) Compounds and methods for the treatment or prevention of flavivirus infections
KR101058696B1 (ko) 후라비바이러스 감염의 치료 또는 예방을 위한 화합물과방법
BRPI0314344B1 (pt) composto 2,3-diidro-6-nitroimidazo[2,1-b]oxazol, composição farmacêutica compreendendo o mesmo e método para produzir um composto
EP3807261B1 (en) Pyridinyl pyrazoles as modulators of roryt
JP2013512247A (ja) フラビウイルス感染症の治療または予防のための5−アルキニル−チオフェン−2−カルボン酸誘導体およびそれらの使用
JP2007530516A (ja) 抗ウイルス剤として有用な4−カルボキシピラゾール誘導体
AU2011205048B2 (en) Compounds and methods for the treatment or prevention of flavivirus infections
HK1112910B (en) Compounds and methods for the treatment or prevention of flavivirus infections
CN118666813A (zh) 三嗪类化合物及其在药物中的应用
HK1177453A (en) Compounds and methods for the treatment or prevention of flavivirus infections

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU